Business News

The final approval has been received from US health regulators to manufacture the Ibuprofen capsules, which is used as a pain reliever and fever reducer. Now the Aurobindo pharma will manufacture and do the marketing of Ibuprofen. The launching of the product will be in September, 2018 and it’s the generic equivalent Pfizer's Advil Liqui-Gels …

The drug major Lupin has collaborated with the Mylan for commercialising Enbrel for the treatment of Arthritis. Basically, Embrel is an autoimmune disorder drug. The Mylan will make Lupin’s proposed Embrel biosimilar in countries like Europe, Australia, New Zealand, Latin America, Africa and in the markets in Asia. Embrel (etanercept) biosimilar is the identical copy …

As per the report which has not been public that encouraged the Indian pharma industry to work with the Chinese but is careful with their intellectual properties. While looking at the Chinese market it’s the second largest pharmaceutical industry so for India it will be beneficial in order to gain market access to the market. …

Thursday morning the pharma stocks were doing great trade whereas the rupee was falling in front of US dollar, the rupee opened with all-time low against the US dollar rupturing 69 level for the first time. The nifty pharma index was trading 0.85 per cent up at 9,317 around 10 am. rn The shares of …

This Tuesday till afternoon it was recorded that the Pharma stocked had a mixed trade, the Nifty indexed of pharma was trading 0.17 per cent down at 9,271. Glenmark and Dr. Reddy’s Laboratories were also among losers in the pharma index. The Cipla (down 1.88 per cent), Candila Healthcare (down 1.46 per cent), Lupin (down …

Indian pharmaceutical sector is now blooming again after plenty of ups and down in past few years handling plenty of regulatory challenges such as recast of FDI policy, patent protection, pricing policies of the US generic market, regulatory approvals, compulsory licensing, QC standards etc. Implementation of the GST, less new products launching and high competition …

The National Anti-Profiteering Authority (NAA) are questioning around 150 consumer goods and pharma companies regarding their stocks with the distributors and stockists on June 30,2017 were sold at low cost after the GST rollout. These were some of the questions the NAA investigators are looking for answers. The NAA issues a letter to top leading …

Finally, Indian pharma companies are finding a way to enter the world’s second largest pharmaceutical market which is attractive and profitable market of China. Usually it takes 5 years to get n approval but the Indian drug regulators get the approval for the drug product within 3-6 months. “They (the China Food and Drug Administration, …

On Tuesday’s trading session the pharma stocks were down during the last hour, the Biocon was down 1.52 percent, Sun Pharmaceutical industries (down 1.33 percent),Divi’s Laboratories ( down 0.95 percent ), Lupin ( down 0.41 percent ), whereas Aurobindo pharma and Cipla (down 0.38 percent ) were incurring losses, keeping the sectoral index unhappy. Around …

China which is the second largest drug market after US has agreed to provide a specific training programme for the domestic pharmaceutical industries to understand their regulatory system, this will promote the India’s exports, a senior government official said. . rnrn “China has assured us that they would provide a platform for Indian exports of …

As the Sun pharma’s Halol plant got clearance from the US FDA brought the pharma stocks into lime light on Wednesday giving a big relax to the pharma stocks. The Nifty pharma indexed closed at up to 0.9 percent at 8,948.95 and is up to 13 percent from recent lows, showing the improvement of the …

Sun Pharma’s Halol plant in Gujarat, India has finally got some relief from the US FDA after receiving satisfactory report from the Food and drug administration. Since 2014 the plant faces many issues with the manufacturing standards and the pressure was piled up after receiving a warning letter for this plant I Gujarat in 2015. …